CG Oncology, Inc. engages with urology leaders at AUA26 to advance patient care connections

CG Oncology, Inc. engages with urology leaders at AUA26 to advance patient care connections
CG Oncology, Inc. at AUA26

CG Oncology, Inc. is participating at the AUA26 conference, engaging directly with leading figures in the urology and uro-oncology communities.

The company aims to build partnerships and foster connections that drive tangible improvements in patient outcomes. Its presence highlights a continued commitment to collaborating with healthcare professionals and industry peers to support innovation in the field of patient care. Details on new initiatives or partnerships emerging from the event are expected to follow.

CG Oncology, Inc. recently announced its first quarter 2026 financial results and business updates, focusing on advances in urology and NMIBC here. The company has also addressed the persistent risk of bladder cancer recurrence despite currently approved NMIBC therapies here. These efforts align with its ongoing push for improved outcomes in bladder cancer care.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.